EcoDrugPlus

Natriuretic Peptide Receptor 3

Ensembl ID : ENSOMEG00000000070
Gene Symbol: NPR3
3 Cross references
211 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSOMEG00000023936
Gene Symbol: LOC112146115
3 Cross references
197 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSOMEG00000009528
Gene Symbol: LOC112163451
3 Cross references
196 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSOMEG00000014686
Gene Symbol: LOC112158634
3 Cross references
193 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSOMEG00000002178
Gene Symbol: NPY2R
1 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Type 1-Like

Ensembl ID : ENSOMEG00000002100
Gene Symbol: LOC112162046
3 Cross references
135 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSOMEG00000000598
Gene Symbol: LOC112155924
3 Cross references
176 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSOMEG00000001003
Gene Symbol: NTSR1
3 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSOMEG00000021500
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSOMEG00000023654
Gene Symbol: NTRK2
3 Cross references
208 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSOMEG00000000685
Gene Symbol: NTRK3
1 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSOMEG00000018088
Gene Symbol: NTRK3
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).